GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Perlegen to Develop a Breast Cancer Test

  • Perlegen Sciences obtained an exclusive commercial license from University of Cambridge to certain breast cancer markers. The company plans to commercialize a diagnostic test, either directly or through a sublicense agreement with a third party.

    The markers were identified through research conducted by the university, Cancer Research Technology (CRT), and Cancer Research U.K. The study, published in the June issue of Nature, identified novel breast cancer susceptibility markers that are present in approximately 20% of U.K. breast cancer cases. 

    University of Cambridge and CRT will share in any financial returns from the diagnostic product. In addition, University of Cambridge may provide noncommercial licenses to academic researchers.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?